LATEST NEWS

HDL ACQUIRES US LICENSE FOR EARLYCDT-LUNG

Health Diagnostic Laboratory, Inc. has acquired substantially all of the assets of Oncimmune USA LLC, the subsidiary of Oncimmune Ltd.

CLICK HERE FOR PRESS RELEASE

ONCIMMUNE ESTABLISHES SCIENCE COMMITTEE

Oncimmune has established a Science Committee to lead and approve all of the workflow of the Company’s R&D department, ensuring that all research is clearly focused on the interests of the Company.

CLICK HERE FOR COMPANY STATEMENT

85% of lung cancers are diagnosed late stage | EarlyCDT-Lung

85% of lung cancers are diagnosed late stage

Find lung cancer before symptoms appear. EarlyCDT-Lung combined with CT can help.

Learn More
Autoantibodies are detectible up to 5 years before a tumor is visible.

EarlyCDT-Lung:

Panel of autoantibodies to aid in early lung cancer detection

Learn More

When Found Early Stage, 5 Year Survival Rate More Than Triples

Recent NLST Trial further shows 20% mortality improvement. EarlyCDT-Lung can reduce false positives associated with CT.

Learn More

EarlyCDT-Lung is a simple blood test that:

  • Has 5 times better Positive Predictive Value (PPV) than CT
  • Has 7 times fewer false positives than CT
  • Detects all types and all stages of lung cancer, including at the earliest stages
  • Positive test implies 5x risk of cancer
Learn More

Doctors

Your Challenge with Lung Cancer

How to identify the relatively small percentage of lung cancers (5-50 depending on the level of risk), per 1,000, that are present in your high-risk patient population. More….

Use of EarlyCDT-Lung:

  • As a risk assessment test to aid in the early detection of lung cancer in your high-risk patients; most notably long-term smokers and ex-smokers.
  • A new tool to risk stratify pulmonary nodules.

Patients

Brief Overview

EarlyCDT-Lung is a simple blood test which is ordered by a GP, or other suitably qualified medical professional, to aid in the risk assessment and early detection of lung cancer. More…

Risk Assessment:
Subscribe by Email
Your email: